



## NIH AIDS Reagent Program

20301 Century Boulevard  
Building 6, Suite 200  
Germantown, MD 20874  
USA

Phone: 240 686 4740  
Fax: 301 515 4015  
aidsreagent.org

### DATA SHEET

**Reagent:** HIV-1 JR-CSF Infectious Molecular Clone (pYK-JRCSF)

**Catalog Number:** 2708

**Lot Number:** 032602

**Release Category:** C

**Provided:** 1 ml ampicillin-resistant transformed HB101 bacteria.

**Cloning Vector:** pBRN/B.

**Special Characteristics:** pYK-JRCSF is an infectious molecular clone of HIV-1<sub>JR-CSF</sub>, a primary isolate from cerebral spinal fluid obtained from an AIDS patient. Contains 0.5 kb of 3' flanking sequences and 2.2 kb of 5' flanking DNA. This DNA clone was obtained from infected PBL eleven days after initiation of culture. Upon transfection, pYK-JRCSF produces infectious HIV-1 viral particles. JR-CSF infects peripheral blood lymphocytes and macrophages, but does not infect transformed T-cell lines. The virus does not induce syncytia formation.

**Recommended Storage:** -70°C.

**Contributor:** Dr. Irvin SY Chen and Dr. Yoshio Koyanagi.

**References:** Haltiner M, Kempe T, Tijan R. A novel strategy for constructing clustered point mutations. *Nucleic Acids Res* **13**:1015-1025, 1985.  
Koyanagi Y, Miles S, Mitsuyasu RT, Merrill JE, Vinters HV, Chen ISY. Dual infection of the central nervous system by AIDS viruses with distinct cellular tropisms. *Science* **236**:819-822, 1987.  
Cann AJ, Zack JA, Go AS, Arrigo SJ, Koyanagi Y, Green PL, Pang S, Chen ISY. HIV-1 T-cell tropism is determined by events prior to provirus formation. *J Virol* **64**:4735-4742, 1990.

---

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.

**NOTE:**

Acknowledgment for publications should read "The following reagent was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: HIV-1 JR-CSF Infectious Molecular Clone (pYK-JRCFS) from Dr. Irvin SY Chen and Dr. Yoshio Koyanagi." Also include the references cited above in any publications.

**Last Updated:**

August 15, 2017

---

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.